Mounjaro vs Zepbound: Same Drug, Two Different Approved Uses
Mounjaro and Zepbound are the same drug sold under two brand names for two different FDA-approved uses. If you have seen both names and wondered what the difference is, the answer is simple: the approved indication. The molecule inside is tirzepatide in both cases.
Understanding why two brand names exist tells you something directly useful about how GLP-1 drug coverage works.
Why two names for one drug
The FDA approves drugs for specific indications — defined conditions and populations. Eli Lilly filed separate new drug applications for tirzepatide's two uses:
- Mounjaro — approved May 13, 2022 for type 2 diabetes (glycaemic control, administered alongside diet and exercise)
- Zepbound — approved November 8, 2023 for weight management in adults with BMI ≥30, or BMI ≥27 with at least one weight-related comorbidity (hypertension, T2D, dyslipidaemia, sleep apnoea)
The dose range is identical: 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg weekly, titrated upward every four or more weeks. The injection device is the same. The Phase 3 data package is different — SURPASS programme for Mounjaro (T2D), SURMOUNT programme for Zepbound (obesity) — but the clinical experience is continuous.
This is the same structure as Novo Nordisk's semaglutide: Ozempic (T2D label) and Wegovy (obesity label) are also the same molecule sold under two names.
The insurance consequence
The label controls coverage. This is the only practical difference that matters to patients:
| Mounjaro | Zepbound | |
|---|---|---|
| FDA indication | Type 2 diabetes | Obesity / overweight + comorbidity |
| Commercial insurance (T2D) | Typically covered | N/A |
| Commercial insurance (obesity) | Usually denied (off-label) | Plan-dependent; ~49% of large employers cover |
| Medicare Part D (T2D) | Covered | N/A |
| Medicare (obesity) | Not covered (off-label) | Covered from July 2026 (GLP-1 Bridge, $50/mo) |
| Savings card copay (commercial) | ~$25/month (T2D patients) | ~$25/month (obesity patients with coverage) |
| Cash-pay via LillyDirect | Not offered as vials | $299–449/month vials |
The Mounjaro Savings Card reduces the copay to as low as $25/month for T2D patients with commercial insurance. It does not work for Medicaid, Medicare, or Tricare.
The Zepbound Savings Card offers the same commercial-insurance copay assistance — but requires an obesity-label prescription. Patients without commercial insurance who want tirzepatide for weight loss access LillyDirect Zepbound vials at $299–449/month by dose tier.
What this means practically
If you have T2D: Mounjaro is the label, T2D coverage is the easiest path. Commercial insurance + Mounjaro Savings Card = ~$25/month. If you also want weight loss (and most T2D patients do), the weight-loss effect of tirzepatide is fully available on the T2D label — the SURPASS trials showed robust weight loss alongside A1C reduction. You do not need the Zepbound label to get the drug's metabolic benefits.
If you want weight loss without T2D: Zepbound is the appropriate label. Whether your insurance covers it depends on your specific plan. PA, step therapy, and documented comorbidities are usually required. If insurance doesn't cover it, LillyDirect vials are the main self-pay path.
Medicare patients: Mounjaro is covered by Medicare Part D for T2D — you can get it at your plan's copay with that diagnosis. Zepbound for obesity was not covered by Medicare until July 1, 2026, when the Medicare GLP-1 Bridge opened Zepbound KwikPen at a $50/month copay for qualifying patients (BMI ≥30, no T2D restriction in the Bridge programme).
Off-label prescribing: A prescriber can technically write "Mounjaro" for a patient without T2D, but insurance will typically see the diagnosis code and deny — they will say the patient should have a Zepbound prescription for obesity instead. The reverse is also possible: Zepbound can be prescribed off-label in T2D patients, though insurers may require Mounjaro for that indication. The label-matching requirement is insurers enforcing the indication structure, not clinical logic.
Cost comparison for self-pay
For patients paying out of pocket, Lilly has structured the two products differently:
- Mounjaro does not have a widely available direct-to-patient self-pay vial programme comparable to LillyDirect Zepbound.
- Zepbound LillyDirect vials ($299–449/month) are Lilly's designated cash-pay path. Many patients without T2D who need tirzepatide but can't get insurance coverage use this programme.
- Retail list prices for both Mounjaro and Zepbound run $1,060–1,590/month for the pen devices.
The practical result: LillyDirect Zepbound is the accessible self-pay route for tirzepatide. If your insurance covers Mounjaro for T2D, that is almost always cheaper than any self-pay option.
For self-pay pricing across all GLP-1 telehealth platforms, see the cash-pay comparison. For the Mounjaro vs Ozempic mechanism comparison, see Ozempic vs Mounjaro.
Frequently asked questions
Is Mounjaro the same as Zepbound?
Mounjaro and Zepbound both contain tirzepatide, made by Eli Lilly. The molecule, dose range, and mechanism are identical. The difference is the FDA-approved indication: Mounjaro is approved for type 2 diabetes; Zepbound is approved for weight management in adults with BMI ≥30 or ≥27 with at least one comorbidity. This label distinction controls insurance coverage.
Does insurance cover Zepbound for weight loss?
Coverage for Zepbound (obesity label) varies by plan. Roughly 49% of large employer plans covered obesity-indicated GLP-1s as of 2025. Many require prior authorisation and step therapy. Medicare does not cover Zepbound for obesity; it covers Mounjaro for type 2 diabetes. As of July 1, 2026, Medicare covers Zepbound KwikPen at a $50/month copay for qualifying patients under the Medicare GLP-1 Bridge.
Can I use Mounjaro instead of Zepbound to save money?
If you have a type 2 diabetes diagnosis and your insurance covers Mounjaro for T2D, your cost with the Mounjaro Savings Card may be as low as $25/month. Zepbound coverage for obesity is harder to get. Some prescribers write Mounjaro for weight-loss patients who also have T2D specifically because the T2D coverage is more accessible. Without T2D, a prescriber can technically prescribe Mounjaro off-label for obesity, but insurance will typically deny reimbursement and require Zepbound instead.
What are the LillyDirect prices for Zepbound vials?
As of May 2026, LillyDirect Zepbound single-dose vials are available at: $299/month for 2.5 mg; $399/month for 5 mg; $449/month for 7.5 mg, 10 mg, 12.5 mg, and 15 mg. Vials and KwikPen are the same price. This is Lilly's self-pay programme — you draw and inject yourself.
Is the Zepbound pen different from the Mounjaro pen?
The injection devices are functionally the same — both use Lilly's single-dose autoinjector pen. The packaging and labelling differ (Mounjaro = purple branding, Zepbound = teal/navy). The pre-filled pens contain the same tirzepatide concentration at the same dose. Some patients also use Zepbound single-dose vials for self-injection with a separate syringe.